Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles.

Tytuł:
Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles.
Autorzy:
Gaglio SC; Department of Biotechnology, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.
Donini M; Department of Medicine, Section of General Pathology, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy.
Denbaes PE; Department of Biotechnology, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.
Dusi S; Department of Medicine, Section of General Pathology, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy.
Perduca M; Department of Biotechnology, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2021 Apr 07; Vol. 26 (8). Date of Electronic Publication: 2021 Apr 07.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, c1995-
MeSH Terms:
Polylactic Acid-Polyglycolic Acid Copolymer*/chemistry
Anti-Inflammatory Agents/*administration & dosage
Dendritic Cells/*drug effects
Dendritic Cells/*metabolism
Imidazoles/*adverse effects
Inflammation Mediators/*metabolism
Plant Extracts/*administration & dosage
Stilbenes/*administration & dosage
Anti-Inflammatory Agents/chemistry ; Cytokines/metabolism ; Dendritic Cells/immunology ; Drug Carriers/chemistry ; Drug Delivery Systems ; Drug Synergism ; Humans ; Nanoparticles/chemistry ; Plant Extracts/chemistry ; Stilbenes/chemistry
References:
Annu Rev Pathol. 2020 Jan 24;15:123-147. (PMID: 31530089)
Int J Mol Sci. 2018 May 11;19(5):. (PMID: 29751683)
Eur J Immunol. 2012 Oct;42(10):2535-43. (PMID: 23042650)
Cytokine. 2015 Dec;76(2):375-381. (PMID: 26431781)
Toxicol Appl Pharmacol. 2016 May 15;299:78-89. (PMID: 26739622)
Nat Immunol. 2012 Jul 19;13(8):722-8. (PMID: 22814351)
J Mater Chem B. 2018 Mar 28;6(12):1815-1824. (PMID: 32254253)
Inflamm Res. 2013 Jul;62(7):641-51. (PMID: 23685857)
Biomed Pharmacother. 2019 Feb;110:554-560. (PMID: 30530291)
Expert Rev Mol Diagn. 2009 May;9(4):325-41. (PMID: 19435455)
Oncoimmunology. 2020 Jul 21;9(1):1796002. (PMID: 32934889)
Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1-18. (PMID: 19782542)
Immunology. 2010 Apr;129(4):525-35. (PMID: 20002210)
Pharmaceuticals (Basel). 2020 Oct 14;13(10):. (PMID: 33066628)
Eur J Clin Invest. 2018 Nov;48 Suppl 2:e12967. (PMID: 29896919)
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):185-196. (PMID: 30478416)
Hum Exp Toxicol. 2015 Aug;34(8):808-18. (PMID: 25425548)
Cells. 2020 Sep 28;9(10):. (PMID: 32998371)
J Control Release. 2012 Jul 20;161(2):505-22. (PMID: 22353619)
Cell Mol Immunol. 2020 Jun;17(6):587-599. (PMID: 32433540)
Inflammopharmacology. 2011 Feb;19(1):1-19. (PMID: 21072600)
Curr Opin Allergy Clin Immunol. 2020 Feb;20(1):56-63. (PMID: 31789871)
Biomed Pharmacother. 2016 Oct;83:1365-1378. (PMID: 27580456)
Int Immunopharmacol. 2018 Mar;56:105-112. (PMID: 29414639)
Bioorg Med Chem. 2020 Mar 1;28(5):115327. (PMID: 31992476)
Pharm Res. 2002 Oct;19(10):1480-7. (PMID: 12425465)
Polymers (Basel). 2011 Sep 1;3(3):1377-1397. (PMID: 22577513)
Int J Mol Sci. 2020 Feb 17;21(4):. (PMID: 32079307)
J Pharm Pharm Sci. 2013;16(5):821-47. (PMID: 24393558)
J Immunol Methods. 2004 Apr;287(1-2):109-24. (PMID: 15099760)
Inflammation. 2017 Aug;40(4):1285-1296. (PMID: 28484893)
Nat Immunol. 2002 Jun;3(6):499. (PMID: 12032557)
Nanomedicine (Lond). 2011 Aug;6(6):1027-46. (PMID: 21644818)
Int J Mol Sci. 2020 Aug 22;21(17):. (PMID: 32842681)
Front Immunol. 2019 Feb 01;10:133. (PMID: 30774634)
Nat Med. 2015 Jul;21(7):719-29. (PMID: 26121196)
Nat Rev Immunol. 2021 Feb;21(2):101-115. (PMID: 32908299)
Biochem Pharmacol. 2020 May;175:113928. (PMID: 32217101)
Molecules. 2020 Jun 01;25(11):. (PMID: 32492964)
Pak J Pharm Sci. 2010 Oct;23(4):403-8. (PMID: 20884454)
J Drug Target. 2003;11(8-10):495-507. (PMID: 15203918)
J Hematol Oncol. 2020 Aug 3;13(1):107. (PMID: 32746880)
Front Cell Dev Biol. 2020 May 26;8:401. (PMID: 32528961)
J Autoimmun. 2020 Jun;110:102382. (PMID: 31883831)
Grant Information:
FURPERDUCA FUR (Fondo Unico della Ricerca - University of Verona); COOPERINT 2019 University of Verona
Contributed Indexing:
Keywords: PLGA nanoparticles; cytokines; dendritic cells; inflammation; oxyresveratrol
Substance Nomenclature:
0 (Anti-Inflammatory Agents)
0 (Cytokines)
0 (Drug Carriers)
0 (Imidazoles)
0 (Inflammation Mediators)
0 (Plant Extracts)
0 (Stilbenes)
1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
4721-07-7 (puag-haad)
V3DMU7PVXF (resiquimod)
Entry Date(s):
Date Created: 20210430 Date Completed: 20210525 Latest Revision: 20210525
Update Code:
20240104
PubMed Central ID:
PMC8067564
DOI:
10.3390/molecules26082106
PMID:
33916909
Czasopismo naukowe
Oxyresveratrol, a stilbene extracted from the plant Artocarpus lakoocha Roxb., has been reported to provide a considerable anti-inflammatory activity. Since the mechanisms of this therapeutic action have been poorly clarified, we investigated whether oxyresveratrol affects the release of the pro-inflammatory cytokines IL-12, IL-6, and TNF-α by human dendritic cells (DCs). We found that oxyresveratrol did not elicit per se the release of these cytokines, but inhibited their secretion induced upon DC stimulation with R848 (Resiquimod), a well-known immune cell activator engaging receptors recognizing RNA viruses. We then investigated whether the inclusion of oxyresveratrol into nanoparticles promoting its ingestion by DCs could favor its effects on cytokine release. For this purpose we synthesized and characterized poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and we assessed their effects on DCs. We found that bare PLGA nanoparticles did not affect cytokine secretion by resting DCs, but increased IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs, an event known as "priming effect". We then loaded PLGA nanoparticles with oxyresveratrol and we observed that oxyresveratrol-bearing particles did not stimulate the cytokine release by resting DCs and inhibited the PLGA-dependent enhancement of IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs. The results herein reported indicate that oxyresveratrol suppresses the cytokine production by activated DCs, thus representing a good anti-inflammatory and immune-suppressive agent. Moreover, its inclusion into PLGA nanoparticles mitigates the pro-inflammatory effects due to cooperation between nanoparticles and R848 in cytokine release. Therefore, oxyresveratrol can be able to contrast the synergistic effects of nanoparticles with microorganisms that could be present in the patient tissues, therefore overcoming a condition unfavorable to the use of some nanoparticles in biological systems.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies